VivoSeq
Oncology

Malignant Neoplasm

17

Pipeline Programs↗

15

Active Trials↗

10

Companies Involved↗

Malignant Neoplasm is an emerging landscape with 17 programs across 10 companies. The most active players are Degron Therapeutics Co., Imclone, Avyxa.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

32/100

Mech. Concentration

29/100

Completion Rate

75/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

D

Degron Therapeutics Co.

1 program

Phase 1I

Imclone

1 program

Phase 2A

Avyxa

1 program

Phase 2G

Gynecologic Oncology Group

1 program

Phase 2F

Fresenius Kabi Oncology Ltd.

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

12 of 16 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody213%Antibody–drug conjugate213%

Small molecule leads; the ring shows all 16 classified programs, each share of the total. Modality classified for 84% of 19 pipeline programs.

Analysis

Trial Status

20

clinical trials

Recruiting12 · 60%
Completed3 · 15%
Not yet recruiting2 · 10%
Active, not recruiting1 · 5%
Unknown status1 · 5%
Suspended1 · 5%

Clinical Trials

Trial Activity

20 trials

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05000892·15 enrolled
A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)
Recruiting·Merck & Co. logoMerck & Co.·Phase 2·NCT06979596·250 enrolled
A Phase I/II Study of Pembrolizumab (MK-3475) in Japanese Pediatric Participants With Specific Solid Tumors or Lymphomas, or in Japanese Adult Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-G21)
Recruiting·Merck & Co. logoMerck & Co.·Preclinical·NCT07302347·20 enrolled
KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations
Recruiting·Merck & Co. logoMerck & Co.·Phase 2·NCT07252739·130 enrolled
LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
Recruiting·Merck & Co. logoMerck & Co.·Preclinical·NCT07630974·134 enrolled
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Diseases
Recruiting·National Cancer Institute (NCI)·N/A·NCT00026884·5,950 enrolled
Safety and Technical Evaluation of a Robotic Platform (RonovoTM) in Elective Oncological Surgery: A Prospective, Single-Arm, Multi-Specialty Registry
Recruiting·IInstituto do Cancer do Estado de São Paulo·Preclinical·NCT07632638·40 enrolled
A First in Human Phase 1 Open-Label, Multicenter, Dose Escalation and Expansion Study of DEG6498 in Patients With Solid Tumors
Recruiting·DDegron Therapeutics Co.·Phase 1·NCT07244835·100 enrolled
A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of MK-4884 in Participants With Advanced/Metastatic Solid Tumors
Recruiting·Merck & Co. logoMerck & Co.·Phase 1·NCT07600749·120 enrolled
Molecular Genetics Studies of Cancer Patients and Their Relatives
Recruiting·CCity of Hope Medical Center·N/A·NCT04185935·999,999 enrolled
LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
Recruiting·Merck & Co. logoMerck & Co.·Preclinical·NCT06941272·50 enrolled
Novel Functional Anatomic and Biomarker Indices of Radiation-Induced Female Sexual Toxicities in a Multi-Center Cohort
Recruiting·IIcahn School of Medicine at Mount Sinai·N/A·NCT05394428·300 enrolled
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms
Active, not recruiting·RR-Pharm·Phase 1·NCT06307093·90 enrolled
Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04825938·15 enrolled
The Impact of Body Composition on Setup Errors in Patients Undergoing Radiotherapy With Thermoplastic Mask Immobilization: A Single-Center Prospective Cohort Study
Not yet recruiting·Shijiazhuang People's Hospital·N/A·NCT07676032·150 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)